Proposed Data Collection Submitted for Public Comment and Recommendations, 17600-17602 [2021-06882]
Download as PDF
<![CDATA[
17600
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
Authority: Government in the Sunshine
Act, 5 U.S.C. 552b.
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
Laura E. Sinram,
Acting Secretary and Clerk of the
Commission.
[FR Doc. 2021–07093 Filed 4–1–21; 4:15 pm]
BILLING CODE 6715–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
jbell on DSKJLSW7X2PROD with NOTICES
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in the BHC Act
(12 U.S.C. 1842(c)).
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than May 5, 2021.
A. Federal Reserve Bank of San
Francisco (Sebastian R. Astrada,
Director, Applications) 101 Market
Street, San Francisco, California 94105–
1579:
1. Peak Bancorp, Inc., McCall, Idaho;
to become a bank holding company by
acquiring Idaho First Bank, McCall,
Idaho.
Board of Governors of the Federal Reserve
System, March 31, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–06944 Filed 4–2–21; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
The notificants listed below have
applied under the Change in Bank
Control Act (Act) (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
applications are set forth in paragraph 7
of the Act (12 U.S.C. 1817(j)(7)).
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
standards enumerated in paragraph 7 of
the Act.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington DC 20551–0001, not later
than April 20, 2021.
A. Federal Reserve Bank of
Minneapolis (Chris P. Wangen,
Assistant Vice President), 90 Hennepin
Avenue, Minneapolis, Minnesota
55480–0291:
1. The Bank Share Marital Trust
under the R. James Gesell Declaration of
Trust dated January 13, 2000, as
amended (Bank Share Marital Trust),
and Andrew J. Gesell, individually and
as co-trustee with Heidi R. Gesell of the
Bank Share Marital Trust, all of St.
Paul, Minnesota; to acquire additional
voting shares of Cherokee Bancshares,
Inc., and thereby indirectly acquire
additional voting shares of
BankCherokee, both of St. Paul,
Minnesota. Additionally, Bank Share
Marital Trust; Charles R. Gesell,
individually and as trustee of the
Charles R. Gesell Trust Declaration
under agreement dated December 30,
1999, both of Santa Rosa, California; and
Peter J. Gesell, individually and as
trustee of the Peter J. Gesell Trust
Declaration under agreement dated
December 30, 1999, both of Duluth,
Minnesota; to join the Gesell Family
Shareholder Group, a group acting in
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
concert, to acquire additional voting
shares of Cherokee Bancshares, Inc., and
thereby indirectly acquire voting shares
of BankCherokee.
2. DDS Trust, Preston B. Steele as
trustee, both of Huron, South Dakota; to
acquire voting shares of Leackco Bank
Holding Company, Inc., Huron, South
Dakota, and thereby indirectly acquire
voting shares of American Bank & Trust,
Wessington Springs, South Dakota
B. Federal Reserve Bank of Atlanta
(Kathryn Haney, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309. Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
1. Dennis Randall Aucoin, Slaughter,
Louisiana; to retain voting shares of
Clinton Bancshares, Inc., and thereby
indirectly retain voting shares of
Landmark Bank, both of Clinton,
Louisiana.
2. Lynette Elaine Ligon, Robert David
Ligon, both of Clinton, Louisiana; and
Alison Leslie Ligon, Ethel, Louisiana; to
join the Ligon Family Control Group, a
group acting in concert, to retain voting
control of Clinton Bancshares, Inc., and
thereby indirectly retain voting shares of
Landmark Bank, both of Clinton,
Louisiana.
Board of Governors of the Federal Reserve
System, March 30, 2021.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2021–06888 Filed 4–2–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[60Day–21–21EB; Docket No. ATSDR–2021–
0004]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Agency for Toxic
Substances and Disease Registry
(ATSDR), as part of its continuing effort
to reduce public burden and maximize
the utility of government information,
invites the general public and other
Federal agencies the opportunity to
comment on a proposed and/or
continuing information collection, as
required by the Paperwork Reduction
SUMMARY:
E:\FR\FM\05APN1.SGM
05APN1
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
Act of 1995. This notice invites
comment on a proposed information
collection project titled ‘‘Evaluating the
Association between Serum
Concentrations of Per- and
Polyfluoroalkyl Substances (PFAS) and
Symptoms and Diagnoses of Selected
Acute Viral Illnesses.’’ The proposed
study will examine the relationship
between PFAS serum levels and
susceptibility to certain acute viral
illnesses, including but not limited to
COVID–19.
DATES: ATSDR must receive written
comments on or before June 4, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. ATSDR–2021–
0004 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. ATSDR will post,
without change, all relevant comments
to Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7118; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Evaluating the Impact of Per- and
Polyfluoroalkyl Substances (PFAS)
Exposure on Susceptibility to Viral
Infection—New—Agency for Toxic
Substances and Disease Registry
(ATSDR).
Background and Brief Description
Per- and poly-fluoroalkyl substances
(PFAS) are a large, diverse group of
thousands of chemicals. They have been
used extensively in a wide range of
industrial and consumer applications.
Epidemiological studies have evaluated
the associations between PFAS
exposure and health effects in humans.
Evidence from studies in occupationally
exposed populations, residential
populations exposed to higher levels of
PFAS in drinking water, and studies in
the general population suggest
associations between PFAS and several
health outcomes. Exposure to PFAS is
nearly ubiquitous in the United States.
Epidemiological studies suggest that
PFAS exposure may impact the immune
system and susceptibility to viral
infections; however, there is little
consistency in the results of studies on
PFAS exposure and infectious disease.
The coronavirus disease 2019 (COVID–
19) pandemic presents a unique concern
and opportunity to explore this
association. If PFAS affect the immune
system, it is possible that they could
affect susceptibility to infection with
severe acute respiratory syndrome
coronavirus 2 (SARS-CoV–2), the virus
that causes COVID–19, or could affect
severity of COVID–19.
In 2019 and 2020, the Agency for
Toxic Substances and Disease Registry
(ATSDR) conducted statistically based
PO 00000
Frm 00016
Fmt 4703
Sfmt 4703
17601
biomonitoring PFAS exposure
assessments (EAs) in eight communities
that had documented exposures to
PFAS in drinking water. ATSDR also
supported two EAs that were designed
to test the PFAS Exposure Assessment
Technical Tools (PEATT). PFAS
concentrations were measured in serum
collected from EA and PEATT
assessment participants, and a
questionnaire was administered to
gather information to characterize each
individual’s exposure. These
communities were investigated under
‘‘Per- or Polyfluoroalkyl Substances
Exposure Assessments [PFAS EAs]’’
(OMB Control No. 0923–0059,
expiration date 06/30/2022).
During the same period, ATSDR
initiated a health study at the Pease
International Tradeport that included
measurement of PFAS serum levels and
collection of information about
individual exposures in participants
under ‘‘Human Health Effects of
Drinking Water Exposures to Per- and
Polyfluoroalkyl Substances (PFAS) at
Pease International Tradeport,
Portsmouth, NH (The Pease Study)’’
(OMB Control No. 0923–0061,
expiration date 08/31/2022).
This a new two-year ATSDR
information collection request (ICR) for
a collaborative study between the
National Center for Environmental
Health (NCEH) and ATSDR. This
follow-up study will recruit participants
who were participated in a previous
ATSDR-funded study, who have
existing PFAS serum measurements,
and who have given prior consent for
additional contact from NCEH/ATSDR.
We anticipate that the total number of
participants enrolled in the NCEH/
ATSDR cohorts will be around 4,075
individuals (3,300 adults and 775
children). This study will attempt to
enroll the entire universe of eligible
participants; therefore, our target sample
size is 4,075. The cohorts have a
substantial number of participants with
high PFAS exposure, as well as a
sufficient range of serum PFAS
concentrations to allow examination of
associations between the outcomes and
across a wide range of PFAS exposures.
The objectives are the following: (1)
To examine the association between
PFAS concentrations in serum collected
from existing ATSDR cohorts and the
frequency of occurrence of selected
syndromes (combinations of selfreported symptoms), which will be used
as a proxy for viral infections; and, (2)
to examine the association between
PFAS concentrations in serum collected
from existing ATSDR cohorts and selfreported positive test results indicating
specific viral infections.
E:\FR\FM\05APN1.SGM
05APN1
17602
Federal Register / Vol. 86, No. 63 / Monday, April 5, 2021 / Notices
During the first three months of the
two-year study period, NCEH/ATSDR
will invite and consent approximately
4,075 participants (3,300 adults and 775
children) to complete a new series of
questionnaires to determine whether
PFAS exposure increases susceptibility
to viral infections, including, but not
limited to, COVID–19. Data will be
collected from those who enroll in the
study through an initial paper-based
questionnaire and a series of four
additional questionnaires over a 12- to
14-month period. Follow-up
questionnaires will be offered in two
modes: Web-based and paper-based. It is
estimated that 75 percent of the
participants will choose the web-based
mode. Participants will also be given
symptom diaries to improve recall after
the initial and between each of the
follow-up questionnaires.
The total time burden requested is
12,724 hours annually. There are no
costs to the respondents other than their
time.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hr)
Total annual
burden
(in hr)
Form name
Adults ....................................
Initial Questionnaire—Adult (paper) .............
Follow up Questionnaire—Adult (paper) ......
Follow up Questionnaire—Adult (REDCap)
Symptom Diary .............................................
Initial Questionnaire—Child (paper) .............
Follow up Questionnaire—Child (paper) ......
Follow up Questionnaire—Child (REDCap)
Symptom Diary .............................................
Initial Questionnaire—Child (paper) .............
1,650
412
1,238
1,650
290
72
218
290
75
1
4
4
1
1
4
4
1
1
30/60
30/60
25/60
4
30/60
30/60
25/60
4
30/60
825
825
2,063
6,600
145
145
363
1,160
38
Follow up Questionnaire—Child (paper) ......
Follow up Questionnaire—Child (REDCap)
Symptom Diary .............................................
24
74
98
4
4
1
30/60
25/60
4
49
123
390
.......................................................................
........................
........................
........................
12,724
Children (7–17 years) ...........
Parents of Children (3–6
years).
Total ...............................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–06882 Filed 4–2–21; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Health Statistics
(BSC, NCHS)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice of meeting.
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Board of Scientific Counselors,
National Center for Health Statistics
(BSC, NCHS). This meeting is open to
the public limited only by the audio (via
teleconference) lines available. The
public is welcome to listen to the
meeting, please use the following URL
https://www.cdc.gov/nchs/about/bsc/
bsc_meetings.htm that points to the BSC
homepage. Further information and
meeting agenda will be available on the
SUMMARY:
jbell on DSKJLSW7X2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondent
VerDate Sep<11>2014
17:23 Apr 02, 2021
Jkt 253001
BSC website including instructions for
accessing the live meeting broadcast.
DATES: The meeting will be held on May
19, 2021, from 11:00 a.m. to 5:30 p.m.,
EDT.
ADDRESSES: The teleconference access is
https://www.cdc.gov/nchs/about/bsc/
bsc_meetings.htm.
FOR FURTHER INFORMATION CONTACT:
Sayeedha Uddin, M.D., M.P.H.,
Executive Secretary, NCHS/CDC, Board
of Scientific Counselors, 3311 Toledo
Road, Room 2627, Hyattsville, Maryland
20782, Telephone (301) 458–4303;
Email SUddin@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Board is charged with
providing advice and making
recommendations to the Secretary,
Department of Health and Human
Services; the Director, CDC; and the
Director, NCHS, regarding the scientific
and technical program goals and
objectives, strategies, and priorities of
NCHS.
Matters To Be Considered: The
meeting agenda includes welcome
remarks and a Center update by NCHS
Director; presentation on National
Center for Health Statistics Strategic
Planning; presentation on Synthetic
Data; presentation on Changes in
National Health Interview Survey Data
Collection During the COVID–19
pandemic; presentation on Innovation
in Vital Statistics: Nowcasting
PO 00000
Frm 00017
Fmt 4703
Sfmt 9990
Techniques; and presentation on
Division of Health Care Statistics Cloud
Migration.
Agenda items are subject to change as
priorities dictate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–06905 Filed 4–2–21; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\05APN1.SGM
05APN1
]]>Agencies
[Federal Register Volume 86, Number 63 (Monday, April 5, 2021)]
[Notices]
[Pages 17600-17602]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-06882]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[60Day-21-21EB; Docket No. ATSDR-2021-0004]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Agency for Toxic Substances and Disease Registry (ATSDR),
as part of its continuing effort to reduce public burden and maximize
the utility of government information, invites the general public and
other Federal agencies the opportunity to comment on a proposed and/or
continuing information collection, as required by the Paperwork
Reduction
[[Page 17601]]
Act of 1995. This notice invites comment on a proposed information
collection project titled ``Evaluating the Association between Serum
Concentrations of Per- and Polyfluoroalkyl Substances (PFAS) and
Symptoms and Diagnoses of Selected Acute Viral Illnesses.'' The
proposed study will examine the relationship between PFAS serum levels
and susceptibility to certain acute viral illnesses, including but not
limited to COVID-19.
DATES: ATSDR must receive written comments on or before June 4, 2021.
ADDRESSES: You may submit comments, identified by Docket No. ATSDR-
2021-0004 by any of the following methods:
Federal eRulemaking Portal: Regulations.gov. Follow the
instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. ATSDR will post, without change, all relevant
comments to Regulations.gov.
Please note: Submit all comments through the Federal eRulemaking
portal (regulations.gov) or by U.S. mail to the address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7118; Email:
[email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
Evaluating the Impact of Per- and Polyfluoroalkyl Substances (PFAS)
Exposure on Susceptibility to Viral Infection--New--Agency for Toxic
Substances and Disease Registry (ATSDR).
Background and Brief Description
Per- and poly-fluoroalkyl substances (PFAS) are a large, diverse
group of thousands of chemicals. They have been used extensively in a
wide range of industrial and consumer applications. Epidemiological
studies have evaluated the associations between PFAS exposure and
health effects in humans. Evidence from studies in occupationally
exposed populations, residential populations exposed to higher levels
of PFAS in drinking water, and studies in the general population
suggest associations between PFAS and several health outcomes. Exposure
to PFAS is nearly ubiquitous in the United States.
Epidemiological studies suggest that PFAS exposure may impact the
immune system and susceptibility to viral infections; however, there is
little consistency in the results of studies on PFAS exposure and
infectious disease. The coronavirus disease 2019 (COVID-19) pandemic
presents a unique concern and opportunity to explore this association.
If PFAS affect the immune system, it is possible that they could affect
susceptibility to infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, or could
affect severity of COVID-19.
In 2019 and 2020, the Agency for Toxic Substances and Disease
Registry (ATSDR) conducted statistically based biomonitoring PFAS
exposure assessments (EAs) in eight communities that had documented
exposures to PFAS in drinking water. ATSDR also supported two EAs that
were designed to test the PFAS Exposure Assessment Technical Tools
(PEATT). PFAS concentrations were measured in serum collected from EA
and PEATT assessment participants, and a questionnaire was administered
to gather information to characterize each individual's exposure. These
communities were investigated under ``Per- or Polyfluoroalkyl
Substances Exposure Assessments [PFAS EAs]'' (OMB Control No. 0923-
0059, expiration date 06/30/2022).
During the same period, ATSDR initiated a health study at the Pease
International Tradeport that included measurement of PFAS serum levels
and collection of information about individual exposures in
participants under ``Human Health Effects of Drinking Water Exposures
to Per- and Polyfluoroalkyl Substances (PFAS) at Pease International
Tradeport, Portsmouth, NH (The Pease Study)'' (OMB Control No. 0923-
0061, expiration date 08/31/2022).
This a new two-year ATSDR information collection request (ICR) for
a collaborative study between the National Center for Environmental
Health (NCEH) and ATSDR. This follow-up study will recruit participants
who were participated in a previous ATSDR-funded study, who have
existing PFAS serum measurements, and who have given prior consent for
additional contact from NCEH/ATSDR. We anticipate that the total number
of participants enrolled in the NCEH/ATSDR cohorts will be around 4,075
individuals (3,300 adults and 775 children). This study will attempt to
enroll the entire universe of eligible participants; therefore, our
target sample size is 4,075. The cohorts have a substantial number of
participants with high PFAS exposure, as well as a sufficient range of
serum PFAS concentrations to allow examination of associations between
the outcomes and across a wide range of PFAS exposures.
The objectives are the following: (1) To examine the association
between PFAS concentrations in serum collected from existing ATSDR
cohorts and the frequency of occurrence of selected syndromes
(combinations of self-reported symptoms), which will be used as a proxy
for viral infections; and, (2) to examine the association between PFAS
concentrations in serum collected from existing ATSDR cohorts and self-
reported positive test results indicating specific viral infections.
[[Page 17602]]
During the first three months of the two-year study period, NCEH/
ATSDR will invite and consent approximately 4,075 participants (3,300
adults and 775 children) to complete a new series of questionnaires to
determine whether PFAS exposure increases susceptibility to viral
infections, including, but not limited to, COVID-19. Data will be
collected from those who enroll in the study through an initial paper-
based questionnaire and a series of four additional questionnaires over
a 12- to 14-month period. Follow-up questionnaires will be offered in
two modes: Web-based and paper-based. It is estimated that 75 percent
of the participants will choose the web-based mode. Participants will
also be given symptom diaries to improve recall after the initial and
between each of the follow-up questionnaires.
The total time burden requested is 12,724 hours annually. There are
no costs to the respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total annual
Type of respondent Form name respondents responses per response (in burden (in
respondent hr) hr)
----------------------------------------------------------------------------------------------------------------
Adults........................ Initial 1,650 1 30/60 825
Questionnaire--
Adult (paper).
Follow up 412 4 30/60 825
Questionnaire--
Adult (paper).
Follow up 1,238 4 25/60 2,063
Questionnaire--
Adult (REDCap).
Symptom Diary... 1,650 1 4 6,600
Children (7-17 years)......... Initial 290 1 30/60 145
Questionnaire--
Child (paper).
Follow up 72 4 30/60 145
Questionnaire--
Child (paper).
Follow up 218 4 25/60 363
Questionnaire--
Child (REDCap).
Symptom Diary... 290 1 4 1,160
Parents of Children (3-6 Initial 75 1 30/60 38
years). Questionnaire--
Child (paper).
Follow up 24 4 30/60 49
Questionnaire--
Child (paper).
Follow up 74 4 25/60 123
Questionnaire--
Child (REDCap).
Symptom Diary... 98 1 4 390
---------------------------------------------------------------
Total..................... ................ .............. .............. .............. 12,724
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2021-06882 Filed 4-2-21; 8:45 am]
BILLING CODE 4163-70-P
